EGFR and non-small cell lung carcinoma: Data from ASCO 2024 showed that AFM24, particularly in combination with atezolizumab, achieved an ORR of 26.7% and a mPFS of 5.9 months in EGFR wild-type NSCLC patients who had progressed after chemotherapy and immunotherapy [209].